Results 1 to 10 of about 169 (166)

False memories in Lewy‐body disease [PDF]

Scandinavian Journal of Psychology, 2015
Recently, de Boysson, Belleville, Phillips et al. (2011) found that patients with Lewy‐body disease (LBD) showed significantly lower rates of false memories than healthy controls, using the Deese–Roediger–McDermott (DRM) experimental procedure. Given that this result could be explained by the practically null rate of true recognition in the LBD group ...
Salvador Algarabel, Alfonso Pitarque, Alicia Sales, Juan Carlos Meléndez, Joaquín Escudero   +4 more
openaire   +3 more sources

Diffuse Lewy body disease

Journal of the Neurological Sciences, 2019
Diffuse Lewy body disease, also called dementia with Lewy bodies (DLB), is defined as progressive dementia and pathological Lewy bodies distributed in the central and autonomic nervous systems. The clinical features are dementia, cognitive fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder (RBD).
Yu Wei Lin, Daniel Truong
openaire   +4 more sources

Cortical Lewy body disease [PDF]

Journal of Neurology, Neurosurgery & Psychiatry, 2004
Cortical Lewy body disease reflects the presence of cortical Lewy bodies but without a clear clinical correlation Cortical Lewy body disease is a pathological observation rather than a distinct clinicopathological entity. Cortical Lewy bodies (CLB) are typically found in Parkinson’s disease and dementia with Lewy bodies (DLB), although they may also ...
openaire   +2 more sources

Parkin disease and the Lewy body conundrum

Movement Disorders, 2013
A clear pathologic hallmark like that identified in sporadic Parkinson’s disease (PD) is lacking in many of the monogenic causes of PD. In leucine-rich repeat kinase 2 (LRRK2) mutations (PARK8), alpha-synuclein pathology in the form of Lewy bodies (LBs) is frequently, but not consistently, observed. Other pathologies reported in LRRK2 cases include tau
Doherty, KM, Hardy, J
openaire   +3 more sources

Lewy body disease and dementia with Lewy bodies

Proceedings of the Japan Academy, Series B, 2014
In 1976 we reported our first autopsied case with diffuse Lewy body disease (DLBD), the term of which we proposed in 1984. We also proposed the term "Lewy body disease" (LBD) in 1980. Subsequently, we classified LBD into three types according to the distribution pattern of Lewy bodies: a brain stem type, a transitional type and a diffuse type.
openaire   +3 more sources

Parkin Localizes to the Lewy Bodies of Parkinson Disease and Dementia with Lewy Bodies [PDF]

The American Journal of Pathology, 2002
Mutations in alpha-synuclein (alpha S) and parkin cause heritable forms of Parkinson disease (PD). We hypothesized that neuronal parkin, a known E3 ubiquitin ligase, facilitates the formation of Lewy bodies (LBs), a pathological hallmark of PD. Here, we report that affinity-purified parkin antibodies labeled classical LBs in substantia nigra sections ...
Michael G, Schlossmacher, Matthew P, Frosch, Wei Ping, Gai, Miguel, Medina, Nutan, Sharma, Lysia, Forno, Tomoyo, Ochiishi, Hideki, Shimura, Ronit, Sharon, Nobutaka, Hattori, J William, Langston, Yoshikuni, Mizuno, Bradley T, Hyman, Dennis J, Selkoe, Kenneth S, Kosik   +14 more
openaire   +2 more sources

Diffuse Lewy body disease

Neuropathology, 1998
Diffuse Lewy body disease (DLBD) has been studied from various viewpoints and, although clinical diagnostic criteria for DLBD have been proposed, diagnosis remains difficult. DLBD has been reported to be the second most common form of dementia in the aged, following Alzheimer‐type dementia. It has, however, been clinically under‐diagnosed.
openaire   +6 more sources

Fabry Disease With Concomitant Lewy Body Disease [PDF]

Journal of Neuropathology & Experimental Neurology, 2019
Abstract Although Gaucher disease can be accompanied by Lewy pathology (LP) and extrapyramidal symptoms, it is unknown if LP exists in Fabry disease (FD), another progressive multisystem lysosomal storage disorder. We aimed to elucidate the distribution patterns of FD-related inclusions and LP in the brain of a 58-year-old cognitively ...
Del Tredici, Kelly, Ludolph, Albert C, Feldengut, Simone, Jacob, Christian, Reichmann, Heinz, Bohl, Jürgen R, Braak, Heiko   +6 more
openaire   +3 more sources

Large‐scale bidirectional arrayed genetic screens identify OXR1 and EMC4 as modifiers of αSynuclein aggregation

FEBS Open Bio, EarlyView.
Activation of the mitochondrial protein OXR1 increases pSyn129 αSynuclein aggregation by lowering ATP levels and altering mitochondrial membrane potential, particularly in response to MSA‐derived fibrils. In contrast, ablation of the ER protein EMC4 enhances autophagic flux and lysosomal clearance, broadly reducing α‐synuclein aggregates.
Sandesh Neupane, Lea Nikolić, Lorenzo Maraio, Thomas Goiran, Nathan Karpilovsky, Stefano Sellitto, Vangelis Bouris, Jiang‐An Yin, Ronald Melki, Edward A Fon, Adriano Aguzzi, Elena De Cecco   +11 more
wiley   +1 more source

Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi, Caroline Gochanour, Seung Ho Choi, Hyunkeun Cho, Chelsea Caspell‐Garcia, Christopher Coffey, Michael Brumm, David‐Erick Lafontant, Yuge Xiao, Thomas Tropea, John Seibyl, Caroline Tanner, Charles S. Venuto, Karl Kieburtz, Lana M. Chahine, Kathleen L. Poston, Andrew Siderowf, Kenneth Marek, Tanya Simuni, The Parkinson's Progression Markers Initiative   +19 more
wiley   +1 more source